Canaccord raised the firm’s price target on Inventiva to $20 from $12 and keeps a Buy rating on the shares. The firm said the increase is primarily driven by the adjustment of estimated pricing for lanifibranor and they assume the same wholesale acquisition cost (WAC) pricing for lani as Rezdiffra/resmetirom and also pushed back the anticipated launch year of Lani in the U.S. market from 2026 to 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings
- Inventiva SA ADR Announces Optimistic 2023 Results
- Inventiva’s LEGEND Trial Shows Promising Results
- Inventiva announces LEGEND trial meets primary endpoint
- Inventiva lifts pause on screening for NATiV3 clinical trial
